title: Managing hypertension in patients with chronic kidney disease.
abstract: Chronic kidney disease (CKD) and hypertension are intrinsically linked. Although 59% of the US population will be diagnosed with CKD during their lifetimes, mortality is usually due to a cardiovascular event. Sodium restriction and a combination of a renin-angiotensin-aldosterone medication and a calcium channel blocker are the most effective methods of managing hypertension in patients with CKD.
authors.affiliation: Kim Zuber practices at Metropolitan Nephrology in Alexandria, Va., and is CME chair of the National Kidney Foundation. Cheryl Gilmartin is a clinical assistant professor in the departments of pharmacy practice and nephrology at the University of Illinois Hospital and Health Sciences System in Chicago, Ill. Jane S. Davis is a nurse practitioner at the University of Alabama at Birmingham and a member of the National Kidney Foundation board. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Kim
authors.initials: K
authors.lastname: Zuber
authors.forename: Cheryl
authors.initials: C
authors.lastname: Gilmartin
authors.forename: Jane
authors.initials: J
authors.lastname: Davis
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004232:Diuretics